
Sign up to save your podcasts
Or


On this episode, Bill and Dr. Steve are joined by three members of the Certis Oncology team: CEO Peter Ellman, Dr. Arun Singh M.D., and Surgical Oncologist Dr. Fritz Eilber M.D.
Certis is an early stage biotech company with a focus on advancing translational oncology through the O-PDX technique. O-PDX standing for “patient derived xenografts” are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. Certis acquires intimate knowledge about the biology, chemistry and evolution of individual cancers to empower patients, inform treatment strategies and advance the next generation of oncology therapeutics. We think you’ll be just as inspired by this episode as we are.
Episode Timestamps:
3:40 Why is treating cancer still such a mystery?
4:30 What is cancer?
5:24 What is the Certis Oncology all about?
6:54 Petri Dish vs Mouse Model
7:39 The novelty of using immunosuppressive mice
9:35 How does Certis scale this model to the whole world
10:57 Can you start your oncology treatment with the mouse method via Certis?
12:08 Do insurance companies play ball with mouse model research?
13:15 What should general surgeons outside of Certis be doing with biopsy specimens?
14:32 What is the turnaround time on the mouse model research?
16:27 What is the dynamic with Certis and an individuals specific oncologist?
21:33 Peter Ellman shares how Certis got started
26:00 Does a tumor that is implanted in a mouse have the same likelihood of traveling to other organs as it would in a human?
28:22 Can patients request having work done with Certis?
30:13 Where is Certis getting it’s funding from, and what is the future dynamic with insurance companies?
33:00 Can the model work for other diseases outside cancer?
-----------------
Learn More: Medicine, We’re Still Practicing
Follow Us: Twitter | Facebook | Instagram
Hosted by: Dr. Steven Taback & Bill Curtis
Produced and Edited by: AJ Moseley
Sound Engineering by: Steve Reickeberg
Theme Music by: Celleste and Eric Dick
A CurtCo Media Production
See omnystudio.com/listener for privacy information.
By CurtCo Media5
2525 ratings
On this episode, Bill and Dr. Steve are joined by three members of the Certis Oncology team: CEO Peter Ellman, Dr. Arun Singh M.D., and Surgical Oncologist Dr. Fritz Eilber M.D.
Certis is an early stage biotech company with a focus on advancing translational oncology through the O-PDX technique. O-PDX standing for “patient derived xenografts” are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. Certis acquires intimate knowledge about the biology, chemistry and evolution of individual cancers to empower patients, inform treatment strategies and advance the next generation of oncology therapeutics. We think you’ll be just as inspired by this episode as we are.
Episode Timestamps:
3:40 Why is treating cancer still such a mystery?
4:30 What is cancer?
5:24 What is the Certis Oncology all about?
6:54 Petri Dish vs Mouse Model
7:39 The novelty of using immunosuppressive mice
9:35 How does Certis scale this model to the whole world
10:57 Can you start your oncology treatment with the mouse method via Certis?
12:08 Do insurance companies play ball with mouse model research?
13:15 What should general surgeons outside of Certis be doing with biopsy specimens?
14:32 What is the turnaround time on the mouse model research?
16:27 What is the dynamic with Certis and an individuals specific oncologist?
21:33 Peter Ellman shares how Certis got started
26:00 Does a tumor that is implanted in a mouse have the same likelihood of traveling to other organs as it would in a human?
28:22 Can patients request having work done with Certis?
30:13 Where is Certis getting it’s funding from, and what is the future dynamic with insurance companies?
33:00 Can the model work for other diseases outside cancer?
-----------------
Learn More: Medicine, We’re Still Practicing
Follow Us: Twitter | Facebook | Instagram
Hosted by: Dr. Steven Taback & Bill Curtis
Produced and Edited by: AJ Moseley
Sound Engineering by: Steve Reickeberg
Theme Music by: Celleste and Eric Dick
A CurtCo Media Production
See omnystudio.com/listener for privacy information.

91,109 Listeners

78,338 Listeners

44,015 Listeners

227,718 Listeners

43,572 Listeners

1,868 Listeners

545 Listeners

496 Listeners

3,342 Listeners

1,155 Listeners

703 Listeners

47,934 Listeners

25 Listeners

35 Listeners

23 Listeners

432 Listeners

51 Listeners

11 Listeners

49 Listeners

14,438 Listeners

29,124 Listeners

89 Listeners

37 Listeners

17 Listeners

3 Listeners

64 Listeners